{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:30:53Z","timestamp":1760297453332},"reference-count":35,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2005,2,9]],"date-time":"2005-02-09T00:00:00Z","timestamp":1107907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2005,4]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>The aim of this exploratory study was to investigate associations between irinotecan pharmacokinetic parameters and allelic variants in genes encoding for drug transporters and drug metabolizing enzymes that are involved in irinotecan disposition in Asian patients with cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Irinotecan was administered at 100\u2003mg\u2003m<jats:sup>\u22122<\/jats:sup> over 90\u2003min on a weekly schedule to 29 nasopharyngeal carcinoma patients and pharmacokinetic analysis was performed during the first cycle. All patients were genotyped for allelic variants in genes encoding drug metabolizing enzymes (<jats:italic>CYP3A4<\/jats:italic>, <jats:italic>CYP3A5<\/jats:italic>, <jats:italic>UGT1A1<\/jats:italic>) and drug transporters (<jats:italic>ABCB1<\/jats:italic>, <jats:italic>ABCC2<\/jats:italic> and <jats:italic>ABCG2<\/jats:italic>) that are involved in irinotecan disposition.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the six candidate genes that were analyzed, 11 genetic variants were found. Significant genotypic\u2013phenotypic associations were apparent only for transporter genes. The <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> of irinotecan was significantly lower in patients carrying the CC genotype at exon 26 of the <jats:italic>ABCB1<\/jats:italic> gene compared with those harbouring at least one variant allele (<jats:italic>P\u2003=<\/jats:italic>\u20030.047). Patients harbouring the wild type <jats:italic>ABCG2<\/jats:italic> CTCA genotype were associated with significantly higher values for relative extent of conversion (REC) of irinotecan to SN\u201038 compared with patients carrying at least one deletion CTCA allele (<jats:italic>P\u2003=<\/jats:italic>\u20030.019).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The present exploratory study shows that genetic polymorphisms in drug transporter genes, particularly in <jats:italic>ABCB1<\/jats:italic> and <jats:italic>ABCG2<\/jats:italic> genes, may be important in influencing the pharmacokinetics of irinotecan and its metabolites. The predictive value of the identified allelic variants in the <jats:italic>ABCG2<\/jats:italic> and <jats:italic>ABCB1<\/jats:italic> genes on irinotecan disposition should be further investigated in a larger patient population as well as in other ethnic populations.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2125.2004.02330.x","type":"journal-article","created":{"date-parts":[[2005,3,30]],"date-time":"2005-03-30T10:04:02Z","timestamp":1112177042000},"page":"415-424","source":"Crossref","is-referenced-by-count":75,"title":["Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer"],"prefix":"10.1111","volume":"59","author":[{"given":"Qingyu","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Sparreboom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eng\u2010Huat","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin\u2010Bun","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Poon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmund J. D.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balram","family":"Chowbay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,2,9]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200009283431302"},{"key":"e_1_2_5_3_2","first-page":"4187","article-title":"Intracellular roles of SN\u201038, a metabolite of the camptothecin derivative CPT\u201011, in the antitumour effect of CPT\u201011","volume":"51","author":"Kawato Y","year":"1991","journal-title":"Cancer Res"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00689205"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1997.tb00289.x"},{"key":"e_1_2_5_6_2","first-page":"3689","article-title":"Identification and properties of a major plasma metabolite of irinotecan (CPT\u201011) isolated from the plasma of patients","volume":"56","author":"Rivory LP","year":"1996","journal-title":"Cancer Res"},{"key":"e_1_2_5_7_2","first-page":"578","article-title":"Identification of a new metabolite of CPT\u201011 (irinotecan): Pharmacological properties and activation of SN\u201038","volume":"286","author":"Dodds HM","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2000.tb07039.x"},{"key":"e_1_2_5_9_2","first-page":"2182","article-title":"Clinical pharmacokinetics and metabolism of irinotecan (CPT\u201011)","volume":"7","author":"Mathijssen RH","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70078-0"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008438109725"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI915"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1999.0453"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.054072"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-001-0420-4"},{"key":"e_1_2_5_16_2","first-page":"921","article-title":"ATP\u2010dependent efflux of CPT\u201011 and SN\u201038 by the multidrug resistance protein (MRP) and its inhibition by PAK\u2010104P","volume":"55","author":"Chen ZS","year":"1999","journal-title":"Mol Pharmacol"},{"key":"e_1_2_5_17_2","first-page":"304","article-title":"Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats","volume":"281","author":"Chu XY","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2001.5850"},{"key":"e_1_2_5_19_2","first-page":"3246","article-title":"Irinotecan pathway genotype analysis to predict pharmacokinetics","volume":"9","author":"Mathijssen RHJ","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(92)80156-K"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200302000-00005"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200201000-00012"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-003-0594-2"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200103000-00008"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.1.195"},{"key":"e_1_2_5_26_2","first-page":"4347","article-title":"Phase I and pharmacokinetic study of the camptothecin derivative irinotecan administered on a weekly schedule in cancer patients","volume":"54","author":"De Forni M","year":"1994","journal-title":"Cancer Res"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199733040-00001"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/83.16.1164"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-4781(01)00270-6"},{"key":"e_1_2_5_30_2","first-page":"611","article-title":"C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low level drug resistance","volume":"1","author":"Imai Y","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11669"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.7.3473"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200312000-00005"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1080\/00498250110057341"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2004.01.013"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.tpj.6500072"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2004.02330.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2004.02330.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T03:16:13Z","timestamp":1697426173000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2004.02330.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,9]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["10.1111\/j.1365-2125.2004.02330.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2004.02330.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2,9]]}}}